Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fortress Biotech, Inc. - Common Stock (NQ:FBIO)

3.710 +0.870 (+30.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fortress Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Fortress Biotech Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q2 sales of $18.89 million. Earnings fell to a loss of $53.93 million, resulting in a 9.0% decrease from last quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
  
Via Benzinga
Fortress Biotech: Q2 Earnings Insights
  Fortress Biotech (NASDAQ:FBIO) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
Upgrades 
Via Benzinga
Recap: Fortress Biotech Q4 Earnings
  Fortress Biotech (NASDAQ:FBIO) reported its Q4 earnings results on Monday, March 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
B. Riley Securities Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know
B. Riley Securities has decided to maintain its Buy rating of Fortress Biotech (NASDAQ:FBIO) and lower its price target from $8.00 to $6.00. Shares of Fortress Biotech are trading down 1.01% over the... 
Via Benzinga
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public... 
From MicroCap Rodeo
Via AccessWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Looking Into Fortress Biotech's Return On Capital Employed
Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q4 sales of $18.28 million. Earnings fell to a loss of $68.51 million, resulting in a 49.38% decrease from last quarter. 
Via Benzinga
Fortress Biotech, Inc. (NASDAQ: FBIO) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Benzinga Announces This Week's All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, February 11 at 9:15 am ET. The Lineup 9:15 am... 
Via Benzinga
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public... 
From MicroCap Rodeo
Via AccessWire
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND)... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Calliditas Therapeutics (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue... 
From Aegis Capital Corp.
Via AccessWire
Topics Retirement
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 34.63% to $12.71 during Thursday's pre-market session. The company's market cap stands at $683.4... 
Via Benzinga
18 Stocks Moving in Thursday's Pre-Market Session
Gainers TSR, Inc. (NASDAQ: TSRI) rose 40.2% to $12.89 in pre-market trading after the company reported record revenue for its first quarter. Cemtrex, Inc. (NASDAQ: CETX) rose 34.... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Fortress-Backed Cyprium's Formulated Copper Histidinate Shows Efficacy In Rare Pediatric Disease
Fortress Biotech Inc's (NASDAQ: FBIO) partner company, Cyprium Therapeutics Inc announced results from an efficacy and safety analysis of data ... 
Via Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share... 
Via Benzinga
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Protagenic Therapeutics (NASDAQ:PTIX... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Midatech Pharma (NASDAQ:MTP) share... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 111.41% to $39.26 during Monday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.